Vaxcyte stock sinks despite Phase II IPD vaccine trial success

Vaxcyte stock sinks despite Phase II IPD vaccine trial success

Source: 
Clinical Trials Arena
snippet: 

Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting all endpoints.